Haemonetics (HAE) EBITDA (2009 - 2026)

Haemonetics' EBITDA history runs 18 years deep, the most recent figure standing at -$23.0 million for Q1 2026.

• On a quarterly basis, EBITDA fell 132.28% year-over-year to -$23.0 million in Q1 2026; TTM through Mar 2026 was $156.7 million, a 29.34% decrease from a year earlier, with the FY2026 full-year figure at $156.7 million, down 29.34% from the prior year.
• EBITDA declined to -$23.0 million in Q1 2026 per HAE's latest filing, from $67.4 million in the prior quarter.
• Across five years, EBITDA topped out at $71.3 million in Q1 2025 and bottomed at -$23.0 million in Q1 2026.
• The 5-year median for EBITDA is $44.6 million (2022), against an average of $41.9 million.
• Across the five-year window, EBITDA surged 2113.45% in 2022 and slumped 132.28% in 2026, its largest moves.
• Year by year, EBITDA stood at $43.3 million in 2022, then advanced by 6.24% to $46.0 million in 2023, then increased by 28.39% to $59.0 million in 2024, then advanced by 14.17% to $67.4 million in 2025, then slumped by 134.16% to -$23.0 million in 2026.
• Per Business Quant, the three latest HAE EBITDA figures stand at -$23.0 million (Q1 2026), $67.4 million (Q4 2025), and $58.5 million (Q3 2025).